{"id":4482,"date":"2019-03-21T14:31:13","date_gmt":"2019-03-21T09:01:13","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=4482"},"modified":"2021-07-24T12:57:15","modified_gmt":"2021-07-24T07:27:15","slug":"merck-business-cocktail","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/merck-business-cocktail","title":{"rendered":"The Business Cocktail"},"content":{"rendered":"\n

Biohaven buys PRV from GW Pharmaceuticals for USD 105 million<\/strong><\/p>\n\n\n\n

GW Pharmaceuticals has announced its decision to sell its rare pediatric disease priority review
\nvoucher (PRV) to Biohaven Pharmaceuticals. The voucher was issued under U.S. Food and Drug
\nAdministration programme to accelerate speedy recovery of rare disease. GW received the voucher
\nwhen FDA approved its cannabinoid medicine Epidiolex for treating seizures.<\/p>\n\n\n\n

BioMed Realty acquires Emeryville Center for Innovation<\/strong><\/p>\n\n\n\n

BioMed Realty-a blackstone portfolio company has acquired Emeryville Center for Innovation for USD
\n135 million. This campus acquisition of around 250,000 square foot, six-story life science office building
\nwill help BioMed to dominate the market of Life Sciences in San Francisco.<\/p>\n\n\n\n

Merck, Iktos to explore AI for drug discovery<\/strong><\/p>\n\n\n\n

Merck, a leading science and technology company has decided to use its generative modelling artificial
\nintelligence (AI) technology to facilitate the rapid and cost-effective discovery and design of promising
\nnew compounds in collaboration with Iktos\u2019 AI technology.<\/p>\n\n\n\n

Merck, and GenScript for Cell and Gene Therapy in China<\/strong><\/p>\n\n\n\n

Merck among the only few to industrialize the process of making viral vectors has now announced its
\ndecision to commercialize the Cell and Gene therapy in collaboration with GenScript- a China biotech
\ncompany. Merck will extend its support in processing products, services and staff training to GenScript
\nto accelerate the manufacturing of plasmids and viral vectors.<\/p>\n","protected":false},"excerpt":{"rendered":"

Biohaven buys PRV from GW Pharmaceuticals for USD 105 million GW Pharmaceuticals has announced its decision to sell its rare pediatric disease priority review voucher (PRV) to Biohaven Pharmaceuticals. The voucher was issued under U.S. Food and Drug Administration programme to accelerate speedy recovery of rare disease. GW received the voucher when FDA approved its […]<\/p>\n","protected":false},"author":1,"featured_media":4002,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[2880,2879,1195,2881,2883,2887,2675,163,1840,2882,2885,704,258,2875,2889,2878,395,2876,2888,502,2884,2886,2700,2877],"industry":[17225],"therapeutic_areas":[17235,17278],"class_list":["post-4482","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-ai","tag-artificial-technology","tag-biohaven","tag-biomed-realty","tag-blackstone","tag-cannabinoid","tag-cell-therapy","tag-china","tag-drug-discovery","tag-emeryville-center-of-innovation","tag-epidiolex","tag-fda","tag-gene-therapy","tag-genscript","tag-gw-pharmaceuticals","tag-iktos","tag-merck","tag-plasmid","tag-prv","tag-rare-disease","tag-san-francisco","tag-seizures","tag-usd","tag-viral-vector","industry-pharmaceutical","therapeutic_areas-cell-and-gene-therapy","therapeutic_areas-other-diseases"],"acf":[],"yoast_head":"\nBiohaven buys PRV from GW Pharmaceuticals for USD 105 million<\/title>\n<meta name=\"description\" content=\"Merck, and GenScript for Cell and Gene Therapy in China\ufeff : Merck among the only few to industrialize the process of making viral vectors has now announced..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/merck-business-cocktail\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biohaven buys PRV from GW Pharmaceuticals for USD 105 million\" \/>\n<meta property=\"og:description\" content=\"Merck, and GenScript for Cell and Gene Therapy in China\ufeff : Merck among the only few to industrialize the process of making viral vectors has now announced..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/merck-business-cocktail\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-03-21T09:01:13+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:15+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103831\/pills-943764_1920-1400x1050.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1400\" \/>\n\t<meta property=\"og:image:height\" content=\"1050\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Biohaven buys PRV from GW Pharmaceuticals for USD 105 million","description":"Merck, and GenScript for Cell and Gene Therapy in China\ufeff : Merck among the only few to industrialize the process of making viral vectors has now announced..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/merck-business-cocktail","og_locale":"en_US","og_type":"article","og_title":"Biohaven buys PRV from GW Pharmaceuticals for USD 105 million","og_description":"Merck, and GenScript for Cell and Gene Therapy in China\ufeff : Merck among the only few to industrialize the process of making viral vectors has now announced..","og_url":"https:\/\/www.delveinsight.com\/blog\/merck-business-cocktail","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-03-21T09:01:13+00:00","article_modified_time":"2021-07-24T07:27:15+00:00","og_image":[{"width":1400,"height":1050,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103831\/pills-943764_1920-1400x1050.jpg","type":"image\/jpeg"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/merck-business-cocktail","url":"https:\/\/www.delveinsight.com\/blog\/merck-business-cocktail","name":"Biohaven buys PRV from GW Pharmaceuticals for USD 105 million","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/merck-business-cocktail#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/merck-business-cocktail#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103831\/pills-943764_1920-1400x1050.jpg","datePublished":"2019-03-21T09:01:13+00:00","dateModified":"2021-07-24T07:27:15+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Merck, and GenScript for Cell and Gene Therapy in China\ufeff : Merck among the only few to industrialize the process of making viral vectors has now announced..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/merck-business-cocktail"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/merck-business-cocktail#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103831\/pills-943764_1920-1400x1050.jpg","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103831\/pills-943764_1920-1400x1050.jpg","width":1400,"height":1050,"caption":"merck"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/01\/04103831\/pills-943764_1920-1400x1050-300x225.jpg","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">AI<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Artificial technology<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Biohaven<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">BioMed Realty<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Blackstone<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">cannabinoid<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">cell therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">China<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">drug discovery<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Emeryville Center of Innovation<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Epidiolex<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">FDA<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Gene therapy<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GenScript<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">GW Pharmaceuticals<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Iktos<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Merck<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Plasmid<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">PRV<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Rare Disease<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">San Francisco<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Seizures<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">USD<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">viral vector<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">AI<\/span>","<span class=\"advgb-post-tax-term\">Artificial technology<\/span>","<span class=\"advgb-post-tax-term\">Biohaven<\/span>","<span class=\"advgb-post-tax-term\">BioMed Realty<\/span>","<span class=\"advgb-post-tax-term\">Blackstone<\/span>","<span class=\"advgb-post-tax-term\">cannabinoid<\/span>","<span class=\"advgb-post-tax-term\">cell therapy<\/span>","<span class=\"advgb-post-tax-term\">China<\/span>","<span class=\"advgb-post-tax-term\">drug discovery<\/span>","<span class=\"advgb-post-tax-term\">Emeryville Center of Innovation<\/span>","<span class=\"advgb-post-tax-term\">Epidiolex<\/span>","<span class=\"advgb-post-tax-term\">FDA<\/span>","<span class=\"advgb-post-tax-term\">Gene therapy<\/span>","<span class=\"advgb-post-tax-term\">GenScript<\/span>","<span class=\"advgb-post-tax-term\">GW Pharmaceuticals<\/span>","<span class=\"advgb-post-tax-term\">Iktos<\/span>","<span class=\"advgb-post-tax-term\">Merck<\/span>","<span class=\"advgb-post-tax-term\">Plasmid<\/span>","<span class=\"advgb-post-tax-term\">PRV<\/span>","<span class=\"advgb-post-tax-term\">Rare Disease<\/span>","<span class=\"advgb-post-tax-term\">San Francisco<\/span>","<span class=\"advgb-post-tax-term\">Seizures<\/span>","<span class=\"advgb-post-tax-term\">USD<\/span>","<span class=\"advgb-post-tax-term\">viral vector<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on Mar 21, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on Mar 21, 2019 2:31 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4482","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=4482"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/4482\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/4002"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=4482"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=4482"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=4482"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=4482"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=4482"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}